Angelman Syndrome Pipeline and Clinical Trials Assessment: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Key Companies - Ovid Therapeutics, PTC Therapeutics, Roche, Ionis Pharmaceutical

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Angelman Syndrome pipeline constitutes 12+ key companies continuously working towards developing 15+ Angelman Syndrome treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Angelman Syndrome Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Angelman Syndrome Market.

The Angelman Syndrome Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Angelman Syndrome Pipeline Report: https://www.delveinsight.com/report-store/angelman-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr
• Companies across the globe are diligently working toward developing novel Angelman Syndrome treatment therapies with a considerable amount of success over the years.
• Angelman Syndrome companies working in the treatment market are Ovid Therapeutics, Taysha Gene Therapies, PTC Therapeutics, GEXVal, Roche, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Neuren Pharmaceuticals, and others, are developing therapies for the Angelman Syndrome treatment
• Emerging Angelman Syndrome therapies such as - OV 882, AAV-mediated UBE3A Gene Replacement therapy, GT-AS, GXV-001, RG 6091, ION582, GTX-102, NNZ-2591, and others are expected to have a significant impact on the Angelman Syndrome market in the coming years.
• In July 2022, Neuren Pharmaceuticals Limited initiated an open-label study of the safety, tolerability, and pharmacokinetics of oral NNZ-2591 in Angelman Syndrome. It is a study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Angelman syndrome
• In July 2022, Ultragenyx Pharmaceutical Inc. and GeneTx Biotherapeutics LLC provided a program update on GTX102 for the treatment of Angelman syndrome (AS), including encouraging interim data from the open-label, dose escalating Phase 1/2 study in pediatric patients who have a genetically confirmed diagnosis of full maternal UBE3A gene deletion
• In March 2022, Neuren Pharmaceuticals received regulatory approval in the U.S. and Australia to start its Phase 2 trial of NNZ-2591, an investigational therapy for Angelman syndrome
• In February 2020, GeneTX Biotherapeutics, LLC in collaboration with Ultragenyx Pharmaceutical Inc Initiated a Phase I/II open-label, multiple-dose, dose-escalating clinical trial of the safety and tolerability of GTX-102in pediatric patients with Angelman Syndrome

Angelman Syndrome Overview
Angelman syndrome (AS) is a rare neuro-genetic disorder that occurs in one in 15,000 live births or 500,000 people worldwide. It is caused by a loss of function of the UBE3A gene in the 15th chromosome derived from the mother. Angelman syndrome (AS) is characterized by severe developmental delay or intellectual disability, severe speech impairment, gait ataxia and/or tremulousness of the limbs, and unique behavior with an apparent happy demeanor that includes frequent laughing, smiling, and excitability.

Get a Free Sample PDF Report to know more about Angelman Syndrome Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Emerging Angelman Syndrome Drugs Under Different Phases of Clinical Development Include:
• OV 882: Ovid Therapeutics
• AAV-mediated UBE3A Gene Replacement therapy: Taysha Gene Therapies
• GT-AS: PTC Therapeutics
• GXV-001: GEXVal
• RG 6091: Roche
• ION582: Ionis Pharmaceuticals
• GTX-102: Ultragenyx Pharmaceutical
• NNZ-2591: Neuren Pharmaceuticals

Route of Administration
Angelman Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Intrathecal

Molecule Type
Products have been categorized under various Molecule types, such as
• Small molecules
• Gene therapies

Angelman Syndrome Pipeline Therapeutics Assessment
• Angelman Syndrome Assessment by Product Type
• Angelman Syndrome By Stage and Product Type
• Angelman Syndrome Assessment by Route of Administration
• Angelman Syndrome By Stage and Route of Administration
• Angelman Syndrome Assessment by Molecule Type
• Angelman Syndrome by Stage and Molecule Type

DelveInsight's Angelman Syndrome Report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Angelman Syndrome product details are provided in the report. Download the Angelman Syndrome pipeline report to learn more about the emerging Angelman Syndrome therapies at:
https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Angelman Syndrome Pipeline Analysis:
The Angelman Syndrome pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Angelman Syndrome with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Angelman Syndrome Treatment.
• Angelman Syndrome key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Angelman Syndrome Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Angelman Syndrome market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Angelman Syndrome drugs and therapies- https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Angelman Syndrome Pipeline Market Drivers
• Improving Healthcare Infrastructure, rising investments aimed at research and development activities to extract enhanced and more effective solutions for the treatment of Angelman syndrome, are some of the important factors that are fueling the Angelman Syndrome Market.

Angelman Syndrome Pipeline Market Barriers
• However, lack of awareness regarding the Angelman Syndrome, misdiagnosis of the angelman syndrome as cerebral palsy or autism and other factors are creating obstacles in the Angelman Syndrome Market growth.

Scope of Angelman Syndrome Pipeline Drug Insight
• Coverage: Global
• Key Angelman Syndrome Companies: Ovid Therapeutics, Taysha Gene Therapies, PTC Therapeutics, GEXVal, Roche, Ionis Pharmaceuticals, Ultragenyx Pharmaceutical, Neuren Pharmaceuticals, and others
• Key Angelman Syndrome Therapies: OV 882, AAV-mediated UBE3A Gene Replacement therapy, GT-AS, GXV-001, RG 6091, ION582, GTX-102, NNZ-2591, and others
• Angelman Syndrome Therapeutic Assessment: Angelman Syndrome current marketed and Angelman Syndrome emerging therapies
• Angelman Syndrome Market Dynamics: Angelman Syndrome market drivers and Angelman Syndrome market barriers

Request for Sample PDF Report for Angelman Syndrome Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/angelman-syndrome-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1 Angelman Syndrome Report Introduction
2 Angelman Syndrome Executive Summary
3 Angelman Syndrome Overview
4 Angelman Syndrome- Analytical Perspective In-depth Commercial Assessment
5 Angelman Syndrome Pipeline Therapeutics
6 Angelman Syndrome Late Stage Products (Phase II/III)
7 Angelman Syndrome Mid Stage Products (Phase II)
8 Angelman Syndrome Early Stage Products (Phase I)
9 Angelman Syndrome Preclinical Stage Products
10 Angelman Syndrome Therapeutics Assessment
11 Angelman Syndrome Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Angelman Syndrome Key Companies
14 Angelman Syndrome Key Products
15 Angelman Syndrome Unmet Needs
16 Angelman Syndrome Market Drivers and Barriers
17 Angelman Syndrome Future Perspectives and Conclusion
18 Angelman Syndrome Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Related Reports:
• Foot And Ankle Devices Market: https://www.delveinsight.com/report-store/foot-and-ankle-devices-market
• Hepatitis B Virus Market: https://www.delveinsight.com/infographics/chronic-hepatitis-b-virus-market
• Image Guided Surgery Devices Market: https://www.delveinsight.com/report-store/image-guided-surgery-devices-market
• Bone Anchored Hearing Systems Market: https://www.delveinsight.com/report-store/bone-anchored-hearing-systems-market
• Alopecia Aerata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Pressure Ulcers Market Size: https://www.delveinsight.com/report-store/pressure-ulcers-market
• Alopecia Areata Market: https://www.delveinsight.com/report-store/alopecia-areata-market
• Brain/cranial Implants Market: https://www.delveinsight.com/report-store/brain-implants-market-market
• Global Electrophysiology Devices Market: https://www.delveinsight.com/report-store/electrophysiology-devices-market
• Abetalipoproteinemia Market: https://www.delveinsight.com/report-store/abetalipoproteinemia-market
• Alopecia Market: https://www.delveinsight.com/report-store/androgenetic-alopecia-market
• Hearing Aid Devices Market: https://www.delveinsight.com/report-store/hearing-aid-devices-market
• Hemodynamic Monitoring Systems Market: https://www.delveinsight.com/report-store/hemodynamic-monitoring-system-market
• Neurovascular Devices Market: https://www.delveinsight.com/report-store/neurovascular-devices-interventional-neurology-market
• Parkinson's Disease Market: https://www.delveinsight.com/report-store/parkinsons-disease-market
• Adult Growth Hormone Deficiency Market: https://www.delveinsight.com/report-store/adult-growth-hormone-deficiency-aghd-market
• Pulse Oximeters Market: https://www.delveinsight.com/report-store/pulse-oximeters-market
• Automated External Defibrillators Market: https://www.delveinsight.com/report-store/automated-external-defibrillator-aed-market
• Energy Based Aesthetic Devices Market: https://www.delveinsight.com/report-store/energy-based-aesthetic-devices-market
• Prefilled Syringes Market: https://www.delveinsight.com/report-store/prefilled-syringes-market
• Scleroderma Market: https://www.delveinsight.com/report-store/scleroderma-market
• Human Papilomavirus Market: https://www.delveinsight.com/report-store/human-papillomavirus-hpv-market
• Capnography Device Market: https://www.delveinsight.com/report-store/capnography-devices-market
• Hyperuricemia Market: https://www.delveinsight.com/report-store/hyperuricemia-pipeline-insight
• Atherectomy Devices Market: https://www.delveinsight.com/report-store/atherectomy-devices-market
• Xerostomia Market: https://www.delveinsight.com/report-store/xerostomia-market
• Defibrillators Market: https://www.delveinsight.com/report-store/defibrillator-market
• Blood Glucose Monitoring Systems Market: https://www.delveinsight.com/report-store/blood-glucose-monitoring-systems-market
• Acoustic Neuroma Market: https://www.delveinsight.com/report-store/acoustic-neuroma-market

Contact Us:
Ankit Nigam
Assistant Manager Marketing
info@delveinsight.com
+91-9650213330
https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

This release was published on openPR.